SELLAS Life Sciences to Host Shareholder Update Call on June 3rd
SELLAS Life Sciences Group (Nasdaq: SLS) will hold a Shareholder Update Call on June 3, 2021, at 8:30 a.m. ET, hosted by President & CEO Angelos Stergiou. The call will provide a corporate update on the company’s progress and future plans in developing cancer immunotherapies.
Participants can join via toll-free numbers or online, with a replay available until June 17, 2021. The company's lead product candidate, galinpepimut-S (GPS), targets the WT1 protein for various cancers, while nelipepimut-S (NPS) aims to treat early-stage HER2+ breast cancer.
- None.
- None.
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.
The call will be facilitated by SELLAS’ President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update.
| Event: | Shareholder Update Call |
| Date: | Thursday, June 3, 2021 |
| Time: | 8:30 a.m. ET |
| Live Call: | 1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International) |
| Webcast: | https://www.sellaslifesciences.com/investors/events-and-presentations |
For interested individuals unable to join the conference call, a replay of the call will be available through June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13719788. The online archive of the webcast will be available at https://www.sellaslifesciences.com/investors/events-and-presentations after the conclusion of the call.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
For more information, please contact:
Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707
Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276
FAQ
What is the date and time of the SELLAS Life Sciences call?
Who hosts the SELLAS Life Sciences Shareholder Update Call?
How can I access the live call for SELLAS Life Sciences?
Is there a replay available for the SELLAS Life Sciences call?
What are the main products of SELLAS Life Sciences?
